Zhifei Biotech announced that the recombinant rotavirus subunit vaccine developed by Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has obtained a drug clinical trial approval notice from the State Drug Administration and agreed to carry out clinical trials to prevent acute gastroenteritis caused by rotavirus infection. The vaccine is used to prevent acute gastroenteritis caused by rotavirus infection in infants and children. This approval will not have a significant impact on the company's recent performance, and there is uncertainty about the progress, results, and product launch of subsequent clinical trials.

Zhifei Biotech announced that the recombinant rotavirus subunit vaccine developed by Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has obtained a drug clinical trial approval notice from the State Drug Administration and agreed to carry out clinical trials to prevent acute gastroenteritis caused by rotavirus infection. The vaccine is used to prevent acute gastroenteritis caused by rotavirus infection in infants and children. This approval will not have a significant impact on the company's recent performance, and there is uncertainty about the progress, results, and product launch of subsequent clinical trials.